Hansoh Pharma reports 61.3% response rate for HS-20122 in Phase 1 trial in EGFR-mutant lung cancer after TKI failure

By Public Technologies
  • Hansoh Pharma presented Phase 1 results for cancer drug HS-20122 at ESMO in Madrid on October 24, 2026.
  • The treatment showed antitumor activity across advanced solid tumors, particularly EGFR-mutated lung cancer following failure of EGFR-targeted therapy.
  • Safety was manageable, with most treatment-related adverse events mild to moderate; serious events primarily involved blood abnormalities.
  • The findings support further development in multiple solid tumors, including EGFR-mutated lung cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 25, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.